Newark, CA and Lebanon, NH 4/26/16—DNA2.0, a supplier of bioengineering solutions, has signed a definitive asset purchase agreement to acquire substantially all the assets of MIGS. MIGS is a CRO organization that specializes in antibody and antibody-like molecular humanization and production for preclinical studies using micrograms to grams of protein. Financial details were not disclosed. “With MIGS’ antibody expertise, we now have the ability to go from virtual sequence to producing proteins at gram scale in mammalian cells,” said DNA2.0 Founder and CEO Michael Feldhaus, PhD.